Jazz Pharmaceuticals (MEX:JAZZN) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 24, 2026)


MEX:JAZZN Jazz Pharmaceuticals PLC MEX:JAZZN
73 GF Score
Price MXN2,500.00
GF Value MXN1,641.59
! 6 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Jazz Pharmaceuticals's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

MEX:JAZZN vs ASND, SMMT, BBIO: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Jazz Pharmaceuticals's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jazz Pharmaceuticals Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's Margin of Safety % (DCF Earnings Based) falls into.


MEX:JAZZN
73GF Score
Jazz Pharmaceuticals PLC MEX:JAZZN
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Jazz Pharmaceuticals (MEX:JAZZN) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of MXN2,500.00 is trading 52.3% above its estimated GF Value™ of MXN1,641.59.

Key valuation signals for MEX:JAZZN:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: MXN1,641.59 vs. price of MXN2,500.00 (52.3% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the MEX:JAZZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score

Get the complete analysis for MEX:JAZZN

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,500.00
Price
MXN1,641.59
GF Value